Gastrointestinal Neuroendocrine tumor : A single institution experience of rare cases

Mukesh Sonkaria; R. K. Tanwar; B L Gochar; Deepti Sukheeja; Neelu Vashishtha; Ankur Sharma

Volume : VIII, Issue : IX, September - 2019

Gastrointestinal Neuroendocrine tumor : A single institution experience of rare cases

Mukesh Sonkaria, R. K. Tanwar, B L Gochar, Deepti Sukheeja, Neelu Vashishtha, Ankur Sharma

Abstract :

Objective: Neuroendocrine tumors (NETs) encompass a heterogeneous group of tumors demonstrating varied clinical behavior. The objective was to study the clinicopathologic features, grading, treatment protocols, and prognosis of gastrointestinal neuroendocrine tumor (GI–NET). Materials and Methods: We hereby share our experience 6 cases with GI– NETs with individual primary site. Results: Six cases of GI–NETs were diagnosed. The primary tumors were located in stomach, duodenum, ampulla of vater, pancreas, and appendix. NETs are not peculiar to any age, but the average age varies with the location. Overall NET of stomach and appendix are slightly more common in female whereas duodenum (D–NETs) and pancreas (P–NET) are in males. Patients were asymptomatic or presented with nonspecific symptoms. Surgery was done in all NETs except P–NET and all patient received 3 – 6 cycle of adjuvant chemotherapy as cisplatin & etoposide except appendix (A–NET). Stomach, duodenum and appendix were low grade tumors whereas ampulla of vater was high grade tumor. Mean follow up was 25 months. All patient are alive except patient of D–NET who was lost to follow up. Conclusions: GI‑NETs are uncommon and heterogeneous group of tumors, with a rising incidence.Surgery is choice of treatment, however cisplatin & etoposide based chemotherapy is highly effective in adjuvant & unresectable or metastatic NET. Recently, the newer targeted agents have significant role in patients with metastatic disease and have opened up new avenues in refractory and advanced stage disease.